Click
Chat
 
Du kan vedhæfte PDF, JPG, PNG, DOC(X), XLS(X) og TXT-filer. Klik på ikonet, vælg fil og vent til upload er færdig før du indsender eller uploader endnu en fil.
60
Vedhæft Send
Historik

Vælg chat via ovenstående menu
Luk reklame

      

Coloplast - pænt uden at være prangende


61974 akademikeren 6/11 2012 18:13
Oversigt

 Organic revenue growth was 6%. Revenue in DKK was up by 8% to DKK 11,023m.

 Organic growth rates by business area: Ostomy Care 6%, Continence Care 8% and Urology Care 6%. In Wound &
Skin Care, sales declined by 1% relative to last year.

 Gross profit was up by 12% to DKK 7,345m, bringing the gross Margin to 67% from 65% last year. At constant ex-
change rates, the gross Margin was 66%.

EBIT was up by 26% to DKK 3,255m. The EBIT Margin was 30% against 25% last year. At constant exchange
rates, the EBIT Margin was 29%.

 The net profit for the year was up by 21% to DKK 2,194m, while earnings per share also improved by 21% relative
to last year to DKK 51.5.

 The free cash flow was up by 28% to DKK 2,336m.

 ROIC after tax was 38%, compared with 30% last year.

 The Board of Directors recommends that the shareholders attending the general meeting to be held on 11 Decem-
ber 2012 approve the following proposals:
o to pay a dividend of DKK 20 per share (FY 2010/11: DKK 14), equal to a pay-out ratio of 38%.
o that the Board of Directors be authorised to pay extraordinary dividend during the financial year, if war-
ranted by the company's cash position.
o to make a 1-to-5 Split of the Coloplast share. This will change the nominal Value per share from DKK 5 to
DKK 1.
o that the share capital be reduced by a nominal Value of DKK 5m, equal to 1,000,000 shares each with a
nominal Value of DKK 5.



6/11 2012 23:49 nohope 062000



Well - jeg synes nu det var et godt regnskab - gid der var flere af den slags - især i min portefølje :)



TRÅDOVERSIGT



SENESTE NYHEDER